Renal hücreli karsinomda tümör belirleyicilerindeki gelişmeler

  • Murat Lekili
  • Oktay Üçer

Bull Urooncol 2009;8(3):3-7

The incidence of renal cell carcinoma is in the third place after prostate and bladder cancer. Incidence has been gradually growing in the last two decade and it was reported that 2% of deaths occur due to RCC and 3% of all cancers are RCC. The better understanding of molecular biology caused improving treatment modalities. The most of clear cell ca has Von hippel- Lindau gene defect and this relationship has instructed to investigate new tumor markers. In this review, new tumor markers that have prognostic and predictive value in RCC, have been overviewed in the literature. Carbonic anhydrase IX, VEGF, ADAM10, chemochines, B7-H1, Ki-67, survivin, P-53, GLUT-1, calveolin-1, endoglin, ABCBI and ABCCI have been evaluated in detail.

In conclusion, CAIX and VEGF are the most important potential two biological marker in appropriate diagnosis and management of RCC. Although the validation of new markers have been done, the most widely-known pathway is the relationship between clear cell carcinoma and VHL gene expression. The combination of staging systems and new tumor markers may have provide to predict disease free survival.